Negocios · 24/9/20251 min de lectura
Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications
Traducción automática local · Idioma original de la fuente
Resumen
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 72 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.